The immune checkpoint inhibitors: where are we now?

Nat Rev Drug Discov. 2014 Dec;13(12):883-4. doi: 10.1038/nrd4476. Epub 2014 Oct 27.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • CTLA-4 Antigen / antagonists & inhibitors*
  • CTLA-4 Antigen / immunology
  • Clinical Trials as Topic / trends
  • Drug Discovery / trends*
  • Humans
  • Ipilimumab
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab